INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 1999

Intravenous GLP-1 infusions dose-dependently reduced food, calorie, and fluid intake in healthy men.

Sixteen healthy male volunteers received graded intravenous doses (0, 0.375, 0.75, and 1.5 pmol/kg/min) of synthetic human GLP-1 in a double-blind, placebo-controlled setup. Graded GLP-1 infusions caused a dose-dependent reduction in food intake (maximal inhibition 35%, p<0.001 vs control), calorie intake (32% reduction, p<0.001), and fluid ingestion (18% reduction, p<0.01). At the highest dose, participants reported less hunger and early fullness prior to a meal (p<0.05), with no overt side effects observed.

Study type
Double-blind, placebo-controlled trial
Who was studied
16 healthy male subjects
What was measured
Food intake, calorie intake, fluid ingestion, hunger, and satiety

THE PAPER

Glucagon-like peptide-1: a potent regulator of food intake in humans.

Gutzwiller JP, Göke B, Drewe J, Hildebrand P, Ketterer S, Handschin D, Winterhalder R, Conen D, Beglinger C. Gut, 1999.

PubMed 9862830 ↗DOI 10.1136/gut.44.1.81 ↗

Nutrients & adequacyWeight & appetite

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.